Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice

References

• GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–1788.30496103
   PubMed Web of Science ®Google Scholar
• GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X28822787
   PubMed Web of Science ®Google Scholar
• US Burden of Disease Collaborators. The state of US health, 1990–2016: burden of diseases, injuries, and risk factors among US States. JAMA. 2018;319(14):1444–1472. doi:10.1001/jama.2018.015829634829
   PubMed Web of Science ®Google Scholar
• FordES, MurphyLB, KhavjouO, GilesWH, HoltJB, CroftJB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31–45. doi:10.1378/chest.14-097225058738
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report); 2020 Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed 128, 2020.
   Google Scholar
• BogartM, StanfordRH, LalibertéF, GermainG, WuJW, DuhMS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343–352. doi:10.2147/COPD.S18465330863037
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Anoro® Ellipta® Prescribing Information; 2019 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-MG-IFU.PDF. Accessed 930, 2019.
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals Inc. Stiolto™ Respimat® Summary of Product Characteristics; 2018 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206756s009lbl.pdf. Accessed 930, 2019.
   Google Scholar
• AstraZeneca Pharmaceuticals LP. Bevespi Aerosphere™ Prescribing Information; 2019 Available from: http://www.azpicentral.com/bevespi/bevespi_pi.pdf. Accessed 72, 2019.
   Google Scholar
• Novartis Pharmaceuticals Corporation. Utibron™ Neohaler® Prescribing Information; 2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207930s002lbl.pdf. Accessed 1013, 2017.
   Google Scholar
• MahlerDA, KerwinE, AyersT, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(9):1068–1079. doi:10.1164/rccm.201505-1048OC26177074
   PubMed Web of Science ®Google Scholar
• DonohueJF, Maleki-YazdiMR, KilbrideS, MehtaR, KalbergC, ChurchA. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.00123830094
   PubMed Web of Science ®Google Scholar
• MartinezFJ, RabeKF, FergusonGT, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017;151(2):340–357. doi:10.1016/j.chest.2016.11.02827916620
   PubMed Web of Science ®Google Scholar
• LipworthBJ, CollierDJ, GonY, et al. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA. Int J Chron Obstruct Pulmon Dis. 2018;13:2969–2984. doi:10.2147/COPD30310273
   PubMed Web of Science ®Google Scholar
• BuhlR, MaltaisF, AbrahamsR, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969–979. doi:10.1183/09031936.0013601425573406
   PubMed Web of Science ®Google Scholar
• WorthH, BuhlR, CriéeCP, KardosP, LossiNS, VogelmeierCF. GOLD 2017 treatment pathways in ‘real life’: an analysis of the DACCORD observational study. Respir Med. 2017;131:77–84. doi:10.1016/j.rmed.2017.08.00828947047
   PubMed Web of Science ®Google Scholar
• SampJC, JooMJ, SchumockGT, CalipGS, PickardAS, LeeTA. Comparative effectiveness of long-acting beta2-agonist combined with a long-acting muscarinic antagonist or inhaled corticosteroid in chronic obstructive pulmonary disease. Pharmacotherapy. 2017;37(4):447–455. doi:10.1002/phar.2017.37.issue-428226405
   PubMed Web of Science ®Google Scholar
• ParkinL, KhuuW, StanbrookMB, TadrousM, MartinsD, GomesT. Trends in the utilisation of COPD therapeutic regimens before and after the introduction of LAMA/LABA combination products: a population-based study. Respir Med. 2018;143:1–7. doi:10.1016/j.rmed.2018.08.00130261979
   PubMed Web of Science ®Google Scholar
• IQVIA. Physician office usage of electronic health records software. A market insights report; 2018 Available from: https://www.iqvia.com/locations/united-states/library/fact-sheets/iqvia-market-insight-report-ehr-software-adoption. Accessed 411, 2019.
   Google Scholar
• Centers for Disease Control and Prevention’s National Center for Health Statistics (NCHS). National Ambulatory Medical Care Survey: 2014 State and National Summary Tables; 2014 Available from: https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2014_namcs_web_tables.pdf. Accessed 217, 2020.
   Google Scholar
• CharlsonME, PompeiP, AlesKL, MacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• DeyoRA, CherkinDC, CiolMA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619. doi:10.1016/0895-4356(92)90133-81607900
   PubMed Web of Science ®Google Scholar
• BatterinkJ, DahriK, AulakhA, RempelC. Evaluation of the use of inhaled medications by hospital inpatients with chronic obstructive pulmonary disease. Can J Hosp Pharm. 2012;65(2):111–118. doi:10.4212/cjhp.v65i2.111822529403
   PubMedGoogle Scholar
• SriramKB, PercivalM. Suboptimal inhaler medication adherence and incorrect technique are common among chronic obstructive pulmonary disease patients. Chron Respir Dis. 2016;13(1):13–22. doi:10.1177/147997231560631326396159
   PubMed Web of Science ®Google Scholar
• KhassawnehBY, Al-AliMK, AlzoubiKH, et al. Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers. Respir Care. 2008;53(3):324–328.18291048
   PubMed Web of Science ®Google Scholar
• van der PalenJ, KleinJJ, van HerwaardenCL, ZielhuisGA, SeydelER. Multiple inhalers confuse asthma patients. Eur Respir J. 1999;14(5):1034–1037. doi:10.1183/09031936.99.1451034910596686
   PubMed Web of Science ®Google Scholar
• DolovichMB, AhrensRC, HessDR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335–371. doi:10.1378/chest.127.1.33515654001
   PubMed Web of Science ®Google Scholar
• Bosnic-AnticevichS, ChrystynH, CostelloRW, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis. 2016;12:59–71.28053517
   PubMed Web of Science ®Google Scholar
• PriceD, ChrystynH, KaplanA, et al. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res. 2012;4(4):184–191. doi:10.4168/aair.2012.4.4.18422754711
   PubMed Web of Science ®Google Scholar
• DavisJR, KernDM, WilliamsSA, et al. Health care utilization and costs after initiating budesonide/formoterol combination or fluticasone/salmeterol combination among COPD patients new to ICS/LABA treatment. J Manag Care Spec Pharm. 2016;22(3):293–304. doi:10.18553/jmcp.2016.22.3.29327003559
   PubMedGoogle Scholar
• BattistiWP, WagerE, BaltzerL, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163(6):461–464. doi:10.7326/M15-028826259067
   PubMed Web of Science ®Google Scholar
• US Census Bureau. OUR DIVERSE POPULATION: race and Hispanic Origin, 2000; 2000 Available from: https://www.census.gov/prod/2001pubs/cenbr01-1.pdf. Accessed 220, 2020.
   Google Scholar